Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224856 | 0.80 | RAB9A (0.61) | RAB9ASMN1; SMN2NOTUMNPC1MEN1 | |
| SCHEMBL4266351 | 0.74 | CYP2A6 (0.45) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP2C9 | |
| SCHEMBL23292571 | 0.74 | NOTUM (0.45) | RAB9ASMN1; SMN2NOTUMNPC1MEN1 | |
| SCHEMBL23292595 | 0.74 | MAOA (0.47) | RAB9ASMN1; SMN2NOTUMNPC1MEN1 | |
| SCHEMBL27293995 | 0.73 | CES1 (0.64) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1493 | 0.73 | CES1 (0.64) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL3045808 | 0.72 | RAB9A (0.64) | RAB9ASMN1; SMN2NOTUMNPC1MEN1 | |
| SCHEMBL5734215 | 0.71 | KDM4E (0.50) | RAB9ANPC1KDRALDH1A1TSHR | |
| Urea SCHEMBL28745676 | 0.71 | CES1 (0.56) | MEN1KMT2AALDH1A1TSHRLMNA | |
| Hydrogen Sulfide SCHEMBL27809609 | 0.71 | CES1 (0.61) | MEN1KMT2AALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | RAB9A 1496/4885SMN1; SMN2 3501/4885NOTUM 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.